ArticleScientific reports2019
Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Proton pump inhibitors and risk of hearing loss; a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence.Pharmacology research & perspectives · 2020Pooled it
- Hewei Jiangni recipe improved the quality of life in patients with cold-heat mixed nonerosive reflux disease: a randomized, double-blinded study.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Trial
- Association of Potentially Inappropriate Medications and Geriatric Nutritional Risk Index with Frailty in Elderly Patients with Ischemic Heart Disease.Diagnostics (Basel, Switzerland) · 2026Article
- Safety of intravenous pantoprazole sodium in paediatric patients aged 1 year to <2 years: a real-world retrospective cohort study in the USA.BMJ paediatrics open · 2026Article
- The prevalence and risk factors of acute kidney injury in post-orthopedic surgery patients.Frontiers in medicine · 2026Article
- E-GastryalJournal of clinical medicine · 2025Article
- Temporal Rule Mining for Enhanced Risk Pattern Extraction: A Case Study with Acute Kidney Injury.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2025Article
- Validation of an interactive process mining methodology for clinical epidemiology through a cohort study on chronic kidney disease progression.Scientific reports · 2024Article
- Proton Pump Inhibitors Induced Hyponatremia in a Liver Transplanted Patient-The Role of Deprescribing: A Case Report and Literature Review.Reports (MDPI) · 2024Article
- Proton pump inhibitors use is associated with a higher prevalence of kidney stones: NHANES 2007-2018.BMC public health · 2024Article
- Proton pump inhibitors and cardiovascular risk: a critical review.Future cardiology · 2024Review
- Seizure and Takotsubo Cardiomyopathy Due to Proton Pump Inhibitor.Journal of community hospital internal medicine perspectives · 2024Article
- Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis.Clinical kidney journal · 2023Review
- Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors.Chonnam medical journal · 2023Review
- Time-dependent association between omeprazole and esomeprazole and hospitalization due to hyponatremia.European journal of clinical pharmacology · 2023Article
- Hippocampal synaptic dysfunction and spatial memory impairment in omeprazole-treated rats.Metabolic brain disease · 2022Article
- Proton pump inhibitors use and risk of incident nephrolithiasis.Urolithiasis · 2022Article
- Article
- Proton pump inhibitors and osteoporosis risk: exploring the role of TRPM7 channel.European journal of clinical pharmacology · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Proton pump inhibitors, PPIs, are widely prescribed and sold globally. Although initially intended for time-limited treatment of acute disorders, such as gastric ulcers and esophagitis, PPIs are now commonly used for prolonged durations and are considered safe for over the counter access. Recent studies have raised concern over associations between PPI use and acute kidney injury, chronic kidney disease, end-stage renal disease, and electrolyte abnormalities. The growing concern over potentially serious adverse drug reactions warrants an evaluation of post marketing surveillance data. In this study of over ten million FDA Adverse Event Reporting System records, we provided evidence of kidney injury and electrolyte imbalances in an alarming number of patients taking PPIs. Additionally, we assessed differences between specific PPIs and observed significant electrolyte and renal abnormalities for each individual drug with varying magnitudes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.